Findings suggest that the patients themselves produce molecules that could reawaken their immune system to battle lung cancerContinue reading
Category Archives: AZBio News
Join Global Leaders in Shaping the Future of Drug Development at C-Path’s 2025 Global Impact Conference
Every Stage, Every Step: Transforming Lives Through Optimized Drug DevelopmentContinue reading
Celebrating Suzanne Pfister’s Legacy
Suzanne Pfister, an extraordinary leader and public servant whose tenure as Vitalyst Health Foundation’s President and CEO transformed the organization and inspired paradigm-shifting change across Arizona’s health landscape.
Continue reading
Stanford faculty member George Tidmarsh, M.D., Ph.D. named Director of Center for Drug Evaluation and Research
The U.S. Food and Drug Administration today announced the appointment of George Francis Tidmarsh, M.D., Ph.D., as Director of the Center for Drug Evaluation and Research (CDER). In this role, Dr. Tidmarsh will lead the FDA’s efforts to ensure safe, effective, and high-quality drugs are available to the American people.Continue reading
Critical Path Institute Appoints Dr. Aoife Brennan to Board of Directors
TUCSON, Ariz., July 16, 2025 — Critical Path Institute® (C-Path) today announced the appointment of Aoife Brennan, M.D., to its Board of Directors. Dr. Brennan brings extensive experience in biopharmaceutical leadership, clinical development, and regulatory strategy to C-Path’s growing efforts to advance global drug development and data-driven science.Continue reading
C-Path’s Translational Therapeutics Accelerator Announces $200,000 Grant for Drug Development Project in Inflammatory Bowel Disease
University Hospitals Cleveland Medical Center physician awarded funding to advance novel therapy for IBD.Continue reading
GT Medical Technologies Completes Final Close of Company’s Oversubscribed $53 Million Series D Equity Financing to Advance Commercial Treatment for Patients with Operable Brain Tumors
July 15, 2025 /PRNewswire/ — GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, today announced the company has completed the close of its oversubscribed $53 million Series D equity financing.Continue reading
Waters and BD’s Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing
- Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters’ proven execution model
- Doubles Waters’ total addressable market to approximately $40 billion, with 5-7% annual growth
- Creates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion
- Increases annual recurring revenue to over 70% with over 80% of revenue coming from iconic market-leading brands
- Anticipate approximately $345 million in annualized EBITDA synergies by 2030, including $200 million of cost synergies by year three, and $290 million of revenue synergies by year five
- Delivers an industry-leading financial outlook with mid-to-high single-digit revenue growth, approximately 500 basis points of adjusted operating margin expansion, and mid-teens annualized adjusted EPS growth expected over five years
- Transaction expected to be accretive to adjusted EPS in the first year
The R & D Expensing Fix in the One Big Beautiful Bill
New tax law restores immediate R&D expensing in the US
C-Path’s Kristen Swingle Named a “Woman Leading the Region” by BizTucson
TUCSON, Ariz., July 9, 2025 — Critical Path Institute® (C-Path) is proud to announce that President and Chief Operating Officer Kristen Swingle, M.S., has been named a 2025 BizTucson “Woman Leading the Region,” an honor recognizing Southern Arizona’s most impactful women in leadership, innovation, and community advancement. Continue reading